Literature DB >> 29984593

Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors.

Robin M Nance1, Heidi M Crane1, Corey Ritchings2, Lisa Rosenblatt2, Matthew Budoff3, Susan R Heckbert1, Daniel R Drozd1, William C Mathews4, Elvin Geng5, Peter W Hunt5, Matthew J Feinstein6, Richard D Moore7, Priscilla Hsue5, Joseph J Eron8, Greer A Burkholder9, Benigno Rodriguez10, Michael J Mugavero9, Michael S Saag9, Mari M Kitahata1, Joseph A C Delaney11.   

Abstract

The Universal Myocardial infarction (MI) definition divides MIs into different types. Type 1 MIs (T1MI) result spontaneously from atherosclerotic plaque instability. Type 2 MIs (T2MI) are due to secondary causes of myocardial oxygen demand/supply mismatch such as occurs with sepsis. T2MI are much more common among those with HIV than in the general population. T1MI and T2MI have different mechanisms, risk factors, and potential treatments suggesting that they should be distinguished to achieve a better scientific understanding of MIs in HIV. We sought to determine whether MI type could be accurately predicted by patient characteristics without adjudication in HIV-infected individuals. We developed a statistical model to predict T2MI versus T1MI using adjudicated events from six sites utilizing demographic characteristics, traditional cardiovascular, and HIV-related risk factors. Validation was assessed in a seventh site via mean calibration, and discrimination level was assessed by the area under the curve (AUC). Of 812 MIs, 388 were T2MI. HIV-related factors including hepatitis C infection were predictive of T2MI, whereas traditional cardiovascular risk factors including total cholesterol predicted T1MI. The score predicted 69 T2MI in the validation sample resulting in poor calibration, given that 90 T2MIs were observed. The development sample AUC was 0.75 versus 0.65 in the validation sample, suggesting relatively poor discrimination. The level of discrimination to predict MI type based on patient characteristics is insufficient for individual level prediction. Adjudication is required to distinguish MI types, which is necessary to advance understanding of this important outcome among HIV populations.

Entities:  

Keywords:  Bayesian model averaging; HIV; adjudication; cardiovascular disease; cohort research; myocardial infarction

Mesh:

Year:  2018        PMID: 29984593      PMCID: PMC6238602          DOI: 10.1089/AID.2018.0053

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  34 in total

1.  Type 2 myocardial infarction in clinical practice.

Authors:  Tomasz Baron; Kristina Hambraeus; Johan Sundström; David Erlinge; Tomas Jernberg; Bertil Lindahl
Journal:  Heart       Date:  2014-10-20       Impact factor: 5.994

2.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

Authors: 
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

3.  The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Melissa Skanderson; Kathleen McGinnis; Lewis H Kuller; Kevin L Kraemer; David Rimland; Matthew B Goetz; Adeel A Butt; Maria C Rodriguez Barradas; Cynthia Gibert; David Leaf; Sheldon T Brown; Jeffrey Samet; Lewis Kazis; Kendall Bryant; Amy C Justice
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-06-28

4.  Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.

Authors:  U H Iloeje; Y Yuan; G L'italien; J Mauskopf; S D Holmberg; A C Moorman; K C Wood; R D Moore
Journal:  HIV Med       Date:  2005-01       Impact factor: 3.180

5.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

6.  HIV infection and the risk of acute myocardial infarction.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Lewis H Kuller; Melissa Skanderson; Elliott Lowy; Kevin L Kraemer; Adeel A Butt; Matthew Bidwell Goetz; David Leaf; Kris Ann Oursler; David Rimland; Maria Rodriguez Barradas; Sheldon Brown; Cynthia Gibert; Kathy McGinnis; Kristina Crothers; Jason Sico; Heidi Crane; Alberta Warner; Stephen Gottlieb; John Gottdiener; Russell P Tracy; Matthew Budoff; Courtney Watson; Kaku A Armah; Donna Doebler; Kendall Bryant; Amy C Justice
Journal:  JAMA Intern Med       Date:  2013-04-22       Impact factor: 21.873

7.  Coronary heart disease in HIV-infected individuals.

Authors:  Judith S Currier; Anne Taylor; Felicity Boyd; Christopher M Dezii; Hugh Kawabata; Beth Burtcel; Jen-Fue Maa; Sally Hodder
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

8.  Study of Cardiovascular Health Outcomes in the Era of Claims Data: The Cardiovascular Health Study.

Authors:  Bruce M Psaty; Joseph A Delaney; Alice M Arnold; Lesley H Curtis; Annette L Fitzpatrick; Susan R Heckbert; Barbara McKnight; Diane Ives; John S Gottdiener; Lewis H Kuller; W T Longstreth
Journal:  Circulation       Date:  2015-11-04       Impact factor: 29.690

9.  The impact of the 2007 ESC-ACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: a retrospective cohort study.

Authors:  Tor Melberg; Robert Burman; Kenneth Dickstein
Journal:  Int J Cardiol       Date:  2008-11-22       Impact factor: 4.164

10.  Systematic adjudication of myocardial infarction end-points in an international clinical trial.

Authors:  Kenneth W Mahaffey; Robert A Harrington; Martijn Akkerhuis; Neal S Kleiman; Lisa G Berdan; Brian S Crenshaw; Barbara E Tardiff; Christopher B Granger; Ingrid DeJong; Manju Bhapkar; Petr Widimsky; Ramón Corbalon; Kerry L Lee; Jaap W Deckers; Maarten L Simoons; Eric J Topol; Robert M Califf
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.